Improving Oncology Outcomes with Data!
COMMENTS: Good story on use of RWE / RWR in oncology. READ TIME: 2 mins *1. “Sir Mick Peake, clinical director for the Centre for Cancer Outcomes within UCLH’s Cancer Continue Reading
COMMENTS: Good story on use of RWE / RWR in oncology. READ TIME: 2 mins *1. “Sir Mick Peake, clinical director for the Centre for Cancer Outcomes within UCLH’s Cancer Continue Reading
IMPACT: The power of numbers…real-world data from 3.5 million vaccinated Israeli’s shows impact/ effectiveness of the Pfizer vaccine during early phase of roll out. READ TIME: 2 min *1. “Among Continue Reading
CONTEXT: Some people lost a small amount of weight whilst in a study….. Interesting thing here is the reporting of RWE data during a study lifetime, which has statistical penalties Continue Reading
CONTEXT: Real world research showing value in rare disease research where RCTs cannot generate the statistical power traditionally needed with so few available patients. New methods to interpret the RWD Continue Reading
IMPACT: Taking insulin and a GLP-1 agonist significantly increases the ability of achievement stable blood sugar levels READ TIME: 2 mins * 1. “Sanofi’s Soliqua combines an insulin with a Continue Reading
Quick Notes: CONTEXT: RWD, RWE, Pfizer, Isaeli Government, Data Transparency, Real-World Epidemiological Evidence Collaboration Agreement IMPACT: Sharing of Real-World Epidemiological Evidence to improve understanding of impact of COVID-19 vaccination Time Continue Reading
EXPERT NOTES: CONTEXT: Peer Reviewed Data, RWE of Effectiveness of Cabozantinib IMPACT: In the largest real-world study to date, cabozantinib was effective in unselected, heavily pretreated patients with mRCC. Initiation Continue Reading
EXPERT NOTES: CONTEXT: Decentralized Clinical Trials IMPACT: Enabling technology for ‘Decentralized Clinical Trials’ a.k.a ‘Virtual Trials’ Time Taken = 2 mins QUOTES FROM SOURCE: 1. “As mentioned earlier, COVID-19 has Continue Reading
Quick Notes: CONTEXT: Japan, Real-World Data IMPACT: Acceptability of RWD in Regulatory Submissions Time to Read = 2 mins Quotes from Source: 1. “TOKYO — Japan’s health ministry will issue Continue Reading
Quick Notes: *Within the report the “conditional marketing authorisations” and “monitoring in real-life” are the “go to” section to see what the post-authorisation obligations were and what the EMA is Continue Reading